You are here:-BPC-157
BPC-1572019-01-01T19:05:31+00:00

BPC-157

Overview

BPC-157 is a synthetic 15 amino acid peptide salt. It is a partial sequence of a naturally occurring gastric peptide with mucosal protective activity called BPC (Body Protective Compound).  The process for the preparation and therapeutic use of BPC is patented.1

The synthetic version of BPC was developed because the naturally occurring BPC, when administered by injection of an aqueous solution or in normal saline, causes pain and/or necrosis. The synthetic version of the peptide does not have these issues, has improved stability in normal saline, and retains the body protective properties of BPC. Unlike most other peptides, which are effective only when injected, BPC-157 is orally bio-available.

As its name implies, BPC-157 exhibits broad body protective effects. It promotes the complex physiological processes that occur during wound healing and tissue regeneration and repair – both inside and outside of the gastrointestinal tract.

Research

BPC-157 has been shown to:

  • decrease pain in injured areas
  • accelerate the healing of many different wounds, including tendons, ligaments, muscles, nervous system, digestive system, teeth, and bone
  • up-regulate growth hormone receptors
  • treat and prevent peptic ulcers
  • improve digestive funcion
  • treat inflammatory bowel disease
  • counter the negative affects of NSAIDs (e.g. naproxen, ibuprofen) on the gut lining
  • protect the liver from toxic insults (e.g. alcohol, antibiotics) and promote healing
  • help cure perdidontitis

Dosing

Anti-aging:

Pulse 4 weeks on/ 2 weeks off

  • Oral: 500 mcg qd
  • SQ injection: 250 mcg qd

Injury/post-surgery

  • Oral: 500 mcg tid
  • SQ injection:  250 mcg tid

Side Effects

BPC-157 is generally well tolerated.  No serious side effects have been reported.  A clinical trial in humans is currently underway to study safety and pharmacokinetics of BPC-157.

As with all subcutaneous injections there is the possibility of an injection site reaction ( e.g. pain, bruising, redness, itching, or swelling)

Other notes

References

  1. “Bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy” [pdf]
  2. Sikiric P, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications” Curr Neuropharmacology (2016) [pubmed] [pdf]
  3. Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract” Current Pharmaceutical Design (2011) [pubmed]
  4. Sikiric P, et al. “A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson’s disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine” Journal of Physiology, Paris. (1999) [pubmed]
  5. “Phase I clinical trial in healthy volunteers to study safety and pharmacokinetics of BPC-157, a pentadecapeptide from gastric source” [web]